Eosinophilic gastroenteritis
diseaseOn this page
Also known as EGEeosinophilic enteritiseosinophilic gastroenterocolitis
Summary
Eosinophilic gastroenteritis (MONDO:0016129) is a disease and 19 clinical trials. Top therapeutic interventions include ondansetron, benralizumab, and mepolizumab. A subtype of gastroenteritis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Prevalence: 1-9 / 100 000 (Worldwide) [Orphanet-validated]
- Phenotypes (HPO): 21
- Clinical trials: 19
Clinical features
Epidemiology
Prevalence records
3 prevalence record(s), Orphanet:
| Type | Class | Value | Geography | Validation |
|---|---|---|---|---|
| Cases/families | 280 | Worldwide | Validated | |
| Point prevalence | 1-9 / 100 000 | 8.4 | Worldwide | Validated |
| Point prevalence | 1-9 / 100 000 | Europe | Not yet validated |
Signs & symptoms
Clinical features (HPO)
21 HPO clinical features (Orphanet curated; top 21 by frequency):
| HPO ID | Term | Frequency |
|---|---|---|
| HP:0001880 | Eosinophilia | Very frequent (80-99%) |
| HP:0001903 | Anemia | Frequent (30-79%) |
| HP:0001974 | Leukocytosis | Frequent (30-79%) |
| HP:0002013 | Vomiting | Frequent (30-79%) |
| HP:0002014 | Diarrhea | Frequent (30-79%) |
| HP:0002015 | Dysphagia | Frequent (30-79%) |
| HP:0002024 | Malabsorption | Frequent (30-79%) |
| HP:0002027 | Abdominal pain | Frequent (30-79%) |
| HP:0002570 | Steatorrhea | Frequent (30-79%) |
| HP:0003073 | Hypoalbuminemia | Frequent (30-79%) |
| HP:0003193 | Allergic rhinitis | Frequent (30-79%) |
| HP:0011024 | Abnormality of the gastrointestinal tract | Frequent (30-79%) |
| HP:0011227 | Elevated circulating C-reactive protein concentration | Frequent (30-79%) |
| HP:0000969 | Edema | Occasional (5-29%) |
| HP:0001047 | Atopic dermatitis | Occasional (5-29%) |
| HP:0001541 | Ascites | Occasional (5-29%) |
| HP:0001824 | Weight loss | Occasional (5-29%) |
| HP:0002099 | Asthma | Occasional (5-29%) |
| HP:0002243 | Protein-losing enteropathy | Occasional (5-29%) |
| HP:0002573 | Hematochezia | Occasional (5-29%) |
| HP:0003565 | Elevated erythrocyte sedimentation rate | Occasional (5-29%) |
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | eosinophilic gastroenteritis |
| Mondo ID | MONDO:0016129 |
| Orphanet | 2070 |
| DOID | DOID:4031 |
| ICD-10-CM | K52.81 |
| NCIT | C35330 |
| SNOMED CT | 359804008 |
| UMLS | C1262481 |
| MedGen | 220382 |
| GARD | 0009142 |
| MedDRA | 10017902 |
| NORD | 1097 |
| Is cancer (heuristic) | no |
Also known as: EGE · eosinophilic enteritis · eosinophilic gastroenteritis · eosinophilic gastroenterocolitis
Data availability: 6 cell lines.
Disease family
This is a subtype of gastroenteritis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › digestive system disorder › intestinal disorder › gastroenteritis › eosinophilic gastroenteritis
Related subtypes (8): inflammatory diarrhea, intestinal infectious disease, intestinal tuberculosis, colitis, appendicitis, campylobacteriosis, Salmonella gastroenteritis, enteritis
Subtypes (2): eosinophilic gastritis, eosinophilic colitis
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 19.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 9 |
| PHASE2 | 4 |
| PHASE3 | 3 |
| PHASE4 | 1 |
| PHASE1/PHASE2 | 1 |
| PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT05439772 | PHASE4 | COMPLETED | Examining the Effect of Ondansetron on Bowel Prep Success |
| NCT04856891 | PHASE3 | COMPLETED | A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic Duodenitis |
| NCT05214768 | PHASE3 | COMPLETED | A Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Japanese Participants With Eosinophilic Gastroenteritis |
| NCT05251909 | PHASE3 | TERMINATED | Efficacy and Safety of Benralizumab in Patients With Eosinophilic Gastritis and/or Gastroenteritis (The HUDSON GI Study) |
| NCT05831176 | PHASE2 | ACTIVE_NOT_RECRUITING | A Study to Learn How Well Dupilumab Works in Adult and Adolescent Participants With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis and the Side Effects it May Have |
| NCT00266565 | PHASE1/PHASE2 | COMPLETED | Anti-Interleukin-5 (IL-5) Study for Hypereosinophilic Syndrome |
| NCT03496571 | PHASE2 | COMPLETED | A Study of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Gastroenteritis |
| NCT03664960 | PHASE2 | COMPLETED | An Extension Study of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Duodenitis |
| NCT03678545 | PHASE2 | COMPLETED | Dupilumab in Eosinophilic Gastritis |
| NCT01814059 | PHASE1 | TERMINATED | Sirolimus for Eosinophil-Associated Gastrointestinal Disorders |
| NCT01793168 | Not specified | RECRUITING | Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford |
| NCT02523118 | Not specified | RECRUITING | OMEGA: Outcome Measures in Eosinophilic Gastrointestinal Disorders Across the Ages |
| NCT05199532 | Not specified | RECRUITING | Eosinophilic Gastrointestinal Disorders Registry |
| NCT00148603 | Not specified | COMPLETED | Montelukast in the Treatment of Duodenal Eosinophilia |
| NCT00267475 | Not specified | COMPLETED | Data Bank for Eosinophilic Disorders |
| NCT01212016 | Not specified | TERMINATED | Immunopathogenesis of Food Allergy and Eosinophilic Gastrointestinal Disorders |
| NCT01779154 | Not specified | WITHDRAWN | Eosinophilic Gastrointestinal Disorders Patient Registry |
| NCT02897271 | Not specified | COMPLETED | Characteristics of Eosinophilic Gastritis, Enteritis, and Colitis in a Multi-Site Cohort |
| NCT03320369 | Not specified | COMPLETED | Effect of Elemental Diet on Adult Patients With Eosinophilic Gastroenteritis |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| ONDANSETRON | 4 | 3 |
| BENRALIZUMAB | 4 | 1 |
| MEPOLIZUMAB | 4 | 1 |
| LIRENTELIMAB | 3 | 3 |
| CENDAKIMAB | 3 | 1 |
Related Atlas pages
- Drugs: Ondansetron, Benralizumab, Mepolizumab, Lirentelimab, Cendakimab